Gustavo Rivero, MD

home / authors / gustavo-rivero-md

Gustavo Rivero, MD, is the director of translational research for myeloid disorders at Tampa General Hospital Cancer Institute in Florida and an associate professor of hematology/oncology.

Articles

Gustavo Rivero, MD, of Tampa General Hospital Cancer Institute

Targeting Menin: A New Frontier in Treating Refractory Leukemias

Gustavo Rivero, MD;David Swoboda, MD

February 28th 2025

Incorporation of menin inhibitors is central to improving the outcome of difficult-to-treat leukemias.

Future Perspectives in Higher-Risk MDS

Gustavo Rivero, MD

July 6th 2022

Dr Gustavo Rivero comments on novel treatment combinations and potential new biomarkers in patients with MDS.

SELECT-MDS-1: Review of Study Design and Objectives

Gustavo Rivero, MD

June 28th 2022

Gustavo Rivero, MD, comments on the ongoing SELECT-MDS-1 trial and as well as reviewing the adverse events of the potential combination of tamibarotene with azacitidine in patients with higher-risk MDS.

A Potential Role for Tamibarotene in the Treatment of Higher-Risk MDS

Gustavo Rivero, MD

June 28th 2022

Dr Gustavo Rivero reviews the treatment options for patients with newly diagnosed higher-risk MDS and discusses tamibarotene’s recent orphan drug designation.

RARA Gene Expression in Higher-Risk MDS

Gustavo Rivero, MD

June 17th 2022

Dr Gustavo Rivero talks about the significance of the RARA gene in patients with higher-risk MDS.

Overview of Myelodysplastic Syndrome and the Importance of Biomarker Testing

Gustavo Rivero, MD

June 17th 2022

An overview of myelodysplastic syndrome (MDS) and the role of biomarker testing in patients with the disorder.